CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
Cobicistat inhibits the enzyme CYP3A and thereby raises the levels of atazanavir or darunavir, which it is taken with. CYP3A also clears cobicistat itself (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). St John's wort induces CYP3A4 and the transporter P-glycoprotein (St John's wort herbal monograph, EMA). The cobicistat documents list St John's wort among strong CYP3A inducers: cobicistat levels may fall, the levels of atazanavir or darunavir follow, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (cobicistat SmPC, EMA, and cobicistat label, US Food and Drug Administration, FDA). For the darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablet, St John's wort may also markedly lower tenofovir alafenamide levels through P-glycoprotein (SmPC of this product, EMA). The documents do not describe any effect of cobicistat on St John's wort.
Symptoms
The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). A rising viral load shows only on blood tests. The Spanish SmPC of a St John's wort product also lists a fall in levels with possible loss of HIV suppression for atazanavir and darunavir (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. St John's wort is on the cobicistat contraindication list of strong CYP3A inducers, together with rifampicin, carbamazepine, phenobarbital and phenytoin (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with atazanavir, darunavir and elvitegravir (SmPCs of these products, EMA). The St John's wort documents do not name cobicistat. Still, the Spanish St John's wort product must not be taken with protease inhibitors, and its interaction table names atazanavir and darunavir, the drugs that cobicistat boosts (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The authorisation of this product has been suspended since June 2026, and there is no other current Spanish St John's wort SmPC. The EMA monograph contraindicates St John's wort with protease inhibitors for well-established use products, and for traditional use products when the daily hyperforin dose exceeds 1 mg (St John's wort herbal monograph, EMA). The cobicistat documents make no such dose exception. Stop St John's wort before starting cobicistat (cobicistat SmPC, EMA, and FDA label). The increased enzyme activity returns to normal within 1 week after St John's wort is stopped (St John's wort herbal monograph, EMA), but the cobicistat documents give no exact interval before cobicistat is started. Before starting cobicistat and during treatment, consider possible interactions and review all concomitant medicines (cobicistat FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat/emtricitabina/tenofovir alafenamida, Symtuza (EU/1/17/1225), sección 4.5 (2026)– EMA, Symtuza 800 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1171225001, consultada 21.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5